Weill Cornell Bone Marrow Transplant Program

Subcutaneous Alemtuzumab

Leave a comment

Alemtuzumab is commonly used in transplant conditioning to prevent graft vs host disease. It is very effective, but when given intravenously it often causes rigors, chills and fevers. Khilna Patel, Pharm D recently reported how Subcutaneous administration is much better tolerated with fewer side-effects, and is equally effective.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation, BBMT Volume 22, Issue 3, March 2016, Pages 456–461

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s